Results 51 to 60 of about 7,834 (208)

Phase I study of the PARP inhibitor talazoparib with radiation therapy for locally recurrent gynecologic cancers

Clinical and Translational Radiation Oncology, 2020
Summary: PARP inhibitors have been shown to radiosensitize tumor cells in both in vitro and in vivo studies. This is a phase I study that aims to determine the safety, tolerability, and maximally tolerated dose of talazoparib, a PARP inhibitor, when ...
David S. Lakomy, Diana L. Urbauer, Shannon N. Westin, Lilie L. Lin   +3 more
doaj   +1 more source

Unique Molecular Features in High-Risk Histology Endometrial Cancers [PDF]

, 2019
Endometrial cancer is the most common gynecologic malignancy in the United States and the sixth most common cancer in women worldwide. Fortunately, most women who develop endometrial cancer have low-grade early-stage endometrioid carcinomas, and simple ...
Collins, Kaitlyn, Hawkins, Shannon M., Jones, Devin E., Pandita, Pooja, Wang, Xiyin   +4 more
core   +1 more source

TALAPRO-3 clinical trial protocol: phase III study of talazoparib plus enzalutamide in metastatic castration-sensitive prostate cancer [PDF]

, 2023
PARP inhibitor; Androgen receptor; EnzalutamideInhibidor de PARP; Receptor de andrógenos; EnzalutamidaInhibidor de PARP; Receptor d'andrògens; EnzalutamidaPoly(ADP-ribose) polymerase inhibitors in combination with androgen-receptor signaling inhibitors ...
Agarwal, Neeraj, Azad, Arun, Mateo, Joaquin, Matsubara, Nobuaki, Saad, Fred, Shore, Neal   +5 more
core   +1 more source

Glutathione Metabolism in Renal Cell Carcinoma Progression and Implications for Therapies [PDF]

, 2019
A significantly increased level of the reactive oxygen species (ROS) scavenger glutathione (GSH) has been identified as a hallmark of renal cell carcinoma (RCC). The proposed mechanism for increased GSH levels is to counteract damaging ROS to sustain the
Meierhofer, David, Xiao, Yi
core   +2 more sources

Combination of Talazoparib and Calcitriol Enhanced Anticancer Effect in Triple−Negative Breast Cancer Cell Lines

Pharmaceuticals, 2022
Monotherapy for triple−negative breast cancer (TNBC) is often ineffective. This study aimed to investigate the effect of calcitriol and talazoparib combination on cell proliferation, migration, apoptosis and cell cycle in TNBC cell lines.
Fu Hou Wong, Vijayaraj Kumar Palanirajan, Edmond Siah Chye Ng, Chung Keat Tan, Eugenie Sin Sing Tan, Farahnaz Amini   +5 more
doaj   +1 more source

Talazoparib, a Poly(ADP-ribose) Polymerase Inhibitor, for Metastatic Castration-resistant Prostate Cancer and DNA Damage Response Alterations: TALAPRO-1 Safety Analyses [PDF]

, 2022
BACKGROUND: The phase II TALAPRO-1 study (NCT03148795) demonstrated durable antitumor activity in men with heavily pretreated metastatic castration-resistant prostate cancer (mCRPC). Here, we detail the safety profile of talazoparib. PATIENTS AND METHODS:
Barthélémy, Philippe, Bimbatti, Davide, Buttigliero, Consuelo, Castro, Elena, Chen, Hsiang-Chun, de Bono, Johann S, Deannuntis, Liza, Di Santo, Nicola, Dorff, Tanya, Dumez, Herlinde, Fizazi, Karim, Healy, Cynthia G, Kilari, Deepak, Machiels, Jean-Pascal, Mehra, Niven, Scagliotti, Giorgio V, Stirling, Adam, van Oort, Inge M   +17 more
core   +2 more sources

Complete response to talazoparib in patient with pancreatic adenocarcinoma harboring somatic PALB2 mutation: A case report and literature review

Frontiers in Oncology, 2022
PARP inhibitors have recently emerged as a maintenance treatment option for metastatic pancreatic cancer patients with germline BRCA mutations. However, the possibility of PARP-inhibitor use as a standalone-targeted therapy for patients with various ...
Andrei Kachmazov, Larisa Bolotina, Anna Kornietskaya, Olesya Kuznetsova, Olesya Kuznetsova, Maxim Ivanov, Alexander Fedenko   +6 more
doaj   +1 more source

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial [PDF]

, 2017
Background: Rucaparib, a poly(ADP-ribose) polymerase inhibitor, has anticancer activity in recurrent ovarian carcinoma harbouring a BRCA mutation or high percentage of genome-wide loss of heterozygosity.
Aghajanian, C, Aghajanian, Carol, Amit, A, Armstrong, D K, Armstrong, Deborah K, Banerjee, S N, Birrer, M J, Bologna, A, Buck, M, Buss, M K, Cameron, Terri, Chambers, S K, Chen, L-m, Clamp, A, Clamp, Andrew, Coleman, R L, Coleman, Robert L, Colombo, N, Colombo, Nicoletta, Dean, A, Dean, Andrew, Denys, H, Dirix, L, Drew, Y, El-Balat, A, Elit, L, Floquet, A, Floquet, Anne, Fong, P C, Fong, Peter C, Friedlander, M L, Gabra, H G, Gancedo, M Amenedo, Gancedo, Margarita Amenedo, Garcia-Donas, J, Garcia-Donas, Jesus, Ghatage, P, Giordano, Heidi, Gladieff, L, Goble, Sandra, Goh, J C, Goh, Jeffrey C, Grace, Caroline, Guerra, E M, Harding, Thomas C, Harnett, P, Herraez, A Casado, Holloway, R W, Holloway, Robert W, Hänle, C, Isaacson, Jeff, Jackson, D, Joly, F, Kichenadasse, G, Konecny, G E, Konecny, Gottfried E, Kovel, S, Krabisch, P, Leary, A, Leary, Alexandra, Ledermann, J A, Ledermann, Jonathan A, Leviov, M, Lin, Kevin K, Lortholary, A, Lorusso, D, Lorusso, Domenica, Lotz, J, Ma, L, Maloney, Lara, McNeish, I A, McNeish, Iain A, Medioni, J, Morgan, M A, Morris, R T, Mutch, D G, Neunhöffer, T, O'Donnell, A, O'Malley, D M, O'Malley, David M, Oaknin, A, Oaknin, Ana, Oza, A M, Oza, Amit M, Palacio, I, Parkinson, C, Pignata, S, Plante, M, Powell, M, Provencher, D, Pölcher, M, Raponi, Mitch, Romero, I, Sabbatini, R F, Safra, T, Sanchez, A, Scambia, G, Scambia, Giovanni, Scott, C L, Scott, Clare L, Shapira-Frommer, R, Slomovitz, B M, Stemmer, S, Sun, James, Swisher, E M, Swisher, Elizabeth M, Tamberi, S, Tredan, O, Vanderkwaak, T, Vergote, I, Vulfovich, M, Weberpals, J I, Weberpals, Johanne I, Welch, S, Wimberger, P, You, B, Zamagni, C   +116 more
core   +1 more source

PARP-inhibitors for BRCA1/2-related advanced HER2-negative breast cancer: A meta-analysis and GRADE recommendations by the Italian Association of Medical Oncology [PDF]

, 2022
Background: Approximately 5-10% of unselected breast cancer (BC) patients retain a hereditary predisposition related to a germline mutation in BRCA1/2 genes.
Biganzoli, Laura, Calabrese, Massimo, Cinquini, Michela, Cortesi, Laura, Criscitiello, Carmen, Del Mastro, Lucia, Delle Piane, Chiara, Dieci, Maria Vittoria, Fittipaldo, Veronica Andrea, Fortunato, Lucio, Franco, Pierfrancesco, Gori, Stefania, Levaggi, Alessia, Marchiò, Caterina, Meduri, Bruno, Miglietta, Federica, Montemurro, Filippo, Zambelli, Alberto   +17 more
core   +2 more sources

Design, Synthesis, and In Vitro Evaluation of the Photoactivatable Prodrug of the PARP Inhibitor Talazoparib

Molecules, 2020
In this article, we report the design, synthesis, photodynamic properties, and in vitro evaluation of photoactivatable prodrug for the poly (ADP-ribose) polymerase 1 (PARP-1) inhibitor Talazoparib.
Jiaguo Li, Dian Xiao, Lianqi Liu, Fei Xie, Wei Li, Wei Sun, Xiaohong Yang, Xinbo Zhou   +7 more
doaj   +1 more source